Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
***
***
New medicines launched by US drug makers reached a median price of $222,003 last year, according to Reuters. These astronomical prices were fueled by three very-expensive gene therapies approved by the FDA. In fact, one of them, from Hemgenix, costs $3.5 million, making it the most expensive drug ever.
Congress did cap annual drug price increases via the Inflation Reduction Act, but that doesn’t cover the cost of new medications. Drug-makers, meanwhile, say the cost of their drugs doesn’t reflect what patients pay out-of-pocket for them.
***
COMMENTS APPRECIATED
Thank You
***
***
Share this:
Filed under: "Advisors Only", "Doctors Only", Drugs and Pharma, Ethics | Tagged: drug makers, Drugs, drugs and money, FDA, FDA drugs money, Hemgenix, Inflation Reduction Act, IRA, new drugs, NEW FDA DRUGS and Money |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Good RX
DEM
LikeLike